MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7017-7026

  Choudhury, Ananya ^a,c   Nelson, Louisa D ^a   Teo, Mark T W ^a   Chilka, Sameer ^a   Bhattarai, Selina ^a   Johnston, Colin F ^a   Elliott, Faye ^a   Lowery, Johanna ^a   Taylor, Claire F ^a   Churchman, Michael ^a   Bentley, Johanne ^a   Knowles, Margaret A ^a   Harnden, Patricia ^a   Bristow, Robert G ^b   Bishop, D Timothy ^a   Kiltie, Anne E ^a,d  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; HISTONE H2AX; KI67; MRE11 PROTEIN; NIBRIN; PROTEIN P53; RAD50 PROTEIN; UNCLASSIFIED DRUG; ATM PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; H2AFX PROTEIN, HUMAN; HISTONE; MRE11A PROTEIN, HUMAN; NBN PROTEIN, HUMAN; NUCLEAR PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN SERINE THREONINE KINASE; RAD50 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DNA DAMAGE; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HYDRONEPHROSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOTHERAPY; TREATMENT OUTCOME; BIOSYNTHESIS; CARCINOMA, TRANSITIONAL CELL; COHORT ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; COHORT STUDIES; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 77956945628     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1202     Document Type: Article

References (37)

1. Cancer incidence - UK statistics [Internet]. London: Cancer Research UK; [updated 2009 Aug 27;cited 2010 Mar 24]. Available from: http://info. cancerresearchuk.org/cancerstats/incidence/.
2. Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008;70:456-63.
3. Moynihan C, Hall E, Lewis R, Birtle A, Mead GM, Huddart R. SPARE: a qualitative study investigating randomization barriers in a Selective Bladder Preservation trial (SBP). J Clin Oncol 2009;27:15s.
4. Colquhoun AJ, Jones GD, Moneef MA, et al. Improving and predicting radiosensitivity in muscle invasive bladder cancer. J Urol 2003; 169:1983-92.
5. Iijima K, Ohara M, Seki R, Tauchi H. Dancing on damaged chromatin: functions of ATM and the RAD50/MRE11/NBS1 complex in cellular responses to DNA damage. J Radiat Res (Tokyo) 2008;49:451-64.
6. Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene 2007;26:7749-58.
7. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8.
8. Arlehag L, Adell G, Knutsen A, Thorstenson S, Sun XF. ATM expression in rectal cancers with or without preoperative radiotherapy. Oncol Rep 2005;14:313-7.
9. Soderlund K, Stal O, Skoog L, Rutqvist LE, Nordenskjold B, Askmalm MS. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys 2007;68:50-8.
10. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6.
11. Hall PA, McCluggage WG. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol 2006;208:1-6.
12. Garcia del Muro X, Condom E, Vigues F, et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004;100:1859-67.
13. Jahnson S, Risberg B, Karlsson MG, Westman G, Bergstrom R, Pedersen J. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol 1995;28:135-42.
14. Moonen L, Ong F, Gallee M, et al. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 2001;49:1305-10.
15. Osen I, Fossa SD, Majak B, Rotterud R, Berner A. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. Br J Urol 1998;81:862-9.
16. Qureshi KN, Griffiths TR, Robinson MC, et al. Combined p21WAF1/ CIP1 and p53 overexpression predict improved survival in muscleinvasive bladder cancer treated by radical radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1234-40.
17. Rotterud R, Berner A, Holm R, Skovlund E, Fossa SD. p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. BJU Int 2001;88:202-8.
18. Wu CS, Pollack A, Czerniak B, et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 1996;47:305-10.
19. Sak SC, Harnden P, Johnston CF, Paul AB, Kiltie AE. APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 2005;11:6205-11.
20. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
21. Borgaonkar S, Jain A, Bollina P, et al. Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique. Clin Oncol (R Coll Radiol) 2002;14:141-7.
22. Chung PW, Bristow RG, Milosevic MF, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 2007;25:303-9.
23. Ribeiro JC, Barnetson AR, Fisher RJ, Mameghan H, Russell PJ. Relationship between radiation response and p53 status in human bladder cancer cells. Int J Radiat Biol 1997;72:11-20.
24. Rodel C, Grabenbauer GG, Rodel F, et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000;46:1213-21.
25. Rhee JG, Li D, Suntharalingam M, Guo C, O'Malley BW, Jr., Carney JP. Radiosensitization of head/neck squamous cell carcinoma by adenovirus-mediated expression of the Nbs1 protein. Int J Radiat Oncol Biol Phys 2007;67:273-8.
26. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.
27. Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 2008;61:1184-92.
28. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;21 Suppl 2:S8-15.
29. Cordon-Cardo C. p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? J Clin Oncol 2004;22:975-7.
30. Giannini G, Ristori E, Cerignoli F, et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 2002;3:248-54.
31. Zhang Y, Lim CU, Williams ES, et al. NBS1 knockdown by small interfering RNA increases ionizing radiation mutagenesis and telomere association in human cells. Cancer Res 2005;65:5544-53.
32. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431-42.
33. Xu X, Stower MJ, Reid IN, Garner RC, Burns PA. A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. Cancer Epidemiol Biomarkers Prev 1997;6:611-6.
34. Hinata N, Shirakawa T, Zhang Z, et al. Radiation induces p53- dependent cell apoptosis in bladder cancer cells with wild-typep53 but not in p53-mutated bladder cancer cells. Urol Res 2003; 31:387-96.
35. Eriksen JG, Alsner J, Steiniche T, Overgaard J. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. Radiother Oncol 2005;76:135-42.
36. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92: 434-44.
37. Saffari B, Bernstein L, Hong DC, et al. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer 2005;15:952-63.